Genesee Capital Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.1M Buy
5,055
+2,161
+75% +$479K 0.46% 49
2025
Q4
$661K Buy
2,894
+526
+22% +$120K 0.27% 70
2025
Q3
$548K Sell
2,368
-2
-0.1% -$407 0.24% 72
2025
Q2
$440K Sell
2,370
-126
-5% -$23.4K 0.2% 80
2025
Q1
$523K Buy
2,496
+177
+8% +$34.4K 0.26% 78
2024
Q4
$412K Buy
2,319
+18
+0.8% +$3.31K 0.19% 84
2024
Q3
$454K Buy
2,301
+15
+0.7% +$2.8K 0.22% 82
2024
Q2
$392K Buy
2,286
+166
+8% +$27.5K 0.19% 81
2024
Q1
$386K Buy
2,120
+240
+13% +$41.4K 0.21% 79
2023
Q4
$291K Buy
1,880
+482
+34% +$70.3K 0.18% 83
2023
Q3
$208K Buy
+1,398
New +$205K 0.15% 84
2023
Q2
Sell
-1,713
Closed -$273K 89
2023
Q1
$273K Buy
+1,713
New +$262K 0.19% 71
2022
Q4
Sell
-2,496
Closed -$335K 80
2022
Q3
$335K Buy
2,496
+183
+8% +$26.3K 0.26% 64
2022
Q2
$354K Buy
2,313
+20
+0.9% +$3.06K 0.25% 70
2022
Q1
$372K Buy
2,293
+184
+9% +$26.7K 0.19% 79
2021
Q4
$286K Buy
2,109
+22
+1% +$2.6K 0.14% 88
2021
Q3
$225K Buy
+2,087
New +$238K 0.11% 103
2021
Q2
Sell
-2,044
Closed -$221K 44
2021
Q1
$221K Buy
2,044
+24
+1% +$2.57K 0.13% 82
2020
Q4
$216K Buy
+2,020
New +$194K 0.14% 75
2020
Q3
Sell
-9,655
Closed -$947K 76
2020
Q2
$947K Buy
+9,655
New +$850K 0.88% 38

Other funds holding ABBV

Genesee Capital Advisors's ABBV Position: Q1 2026 in Review

Genesee Capital Advisors increased its AbbVie (ABBV) stake by 75% in Q1 2026, buying an estimated $479K and bringing the position to 5,055 shares worth $1.1M. The position accounts for 0.46% of the portfolio, ranked #49.

Genesee Capital Advisors first reported a position in ABBV in Q2 2020 and has held it in 20 quarters since. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Genesee Capital Advisors held 5,055 shares of AbbVie worth $1.1M as of Q1 2026.
  • Genesee Capital Advisors bought 2,161 AbbVie shares in Q1 2026, an estimated $479K.
  • AbbVie made up 0.46% of Genesee Capital Advisors's portfolio in Q1 2026, its #49 holding.
  • Genesee Capital Advisors first reported a position in AbbVie in Q2 2020 and has held it in 20 quarters since.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Genesee Capital Advisors's 13F filing for Q1 2026, filed 22 Apr 2026.